Acquired von Willebrand syndrome in patients with a centrifugal or axial continuous flow left ventricular assist device.
نویسندگان
چکیده
OBJECTIVES The aim of this study was to determine whether differences in continuous flow left ventricular assist devices (LVADs) may lead to differences in the von Willebrand profile and the occurrence of bleeding and thromboembolic events. BACKGROUND The HeartMate II (Thoratec Corp., Pleasanton, California) and HeartWare Ventricular Assist Device (HVAD) (HeartWare, Inc., Framingham, Massachusetts) systems are the most frequently implanted LVADs worldwide. In all patients with an axial-flow HeartMate II, acquired von Willebrand syndrome (AvWS) due to the loss of large molecular weight multimers was found. The large molecular weight multimers of the von Willebrand factor (vWF) play a key role in primary hemostasis through interactions with platelets. METHODS This was a retrospective study of the vWF profile and incidence of bleeding and thromboembolic events in 102 patients receiving the HeartMate II (n = 51) and HVAD (n = 51). Between January 2003 and December 2010, vWF testing was performed in 102 of 175 consecutive patients after LVAD implantation. RESULTS AvWS was found in all patients, demonstrated by a decrease in the high molecular weight multimers of vWF to 30 ± 14% in HeartMate II patients and 34 ± 13% in patients with an HVAD. Significant predictors of vWF antigen included age (p = 0.011), number of days on the device (p = 0.035), C-reactive protein (p < 0.001), and blood group (p = 0.007). Bleeding and thromboembolic event rates were similar. However, lower fractions of vWF antigen and high molecular weight multimers did not correlate with the rate of bleeding complications or thromboembolic events. CONCLUSIONS AvWS developed in all patients after centrifugal or axial flow pump implantation. Different patterns of AvWS were seen between the devices as well as individually. However, the complication rates after implantation were similar.
منابع مشابه
Acquired von Willebrand syndrome after exchange of the HeartMate XVE to the HeartMate II ventricular assist device.
Instead of pulsatile ventricular assist devices an increasing number of nonpulsatile ventricular assist devices are introduced to clinical practice. The different flow characteristics of this new technique lead to alteration in shear stress on blood components, which may affect the coagulation system. Repeated von Willebrand factor analyses were performed in a patient who first was implanted wi...
متن کاملEditorial comment: Adverse events in long-term ventricular assist device therapy.
the higher risk of developing a thrombosis anyway. In conclusion, compared with the other study results, our data suggest that a notably mild anticoagulation protocol does not increase the risk of severe thrombo-embolic events in the early and late postoperative period after the implantation of the HM II CW LVAD. Furthermore, this mild regime is helpful in reducing the still unacceptably high i...
متن کاملAcquired von Willebrand syndrome in patients with an axial flow left ventricular assist device.
BACKGROUND Rotary blood pumps used as left ventricular assist devices (LVADs) allow for long-term support and may become suitable alternatives to heart transplantation. Effects of this technology on the coagulation system are not completely understood, leading to controversial anticoagulation protocols. Thus, we investigated the primary hemostasis in patients with chronic LVAD therapy. METHOD...
متن کاملAdvances in Heart Failure Mechanisms of Bleeding and Approach to Patients With Axial-Flow Left Ventricular Assist Devices
During the past several decades, left ventricular assist devices (LVADs) have become a valuable therapeutic option in the management of advanced systolic heart failure. Durable LVADs are being used to provide long-term mechanical circulatory support to a growing population of patients with end-stage systolic heart failure refractory to medical and electric therapies. This advanced stage of hear...
متن کاملWhy pulsatility still matters: a review of current knowledge
Continuous-flow left ventricular assist devices (LVAD) have become standard therapy option for patients with advanced heart failure. They offer several advantages over previously used pulsatile-flow LVADs, including improved durability, less surgical trauma, higher energy efficiency, and lower thrombogenicity. These benefits translate into better survival, lower frequency of adverse events, imp...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
عنوان ژورنال:
- JACC. Heart failure
دوره 2 2 شماره
صفحات -
تاریخ انتشار 2014